Regulatory News:

SuperSonic Imagine (Paris:SSI) (Euronext: SSI, FR0010526814, Eligible PEA-PME), a company specialized in ultrasound medical imaging, today announces its revenue for the 4th quarter and full year to December 31, 2014.

In thousands of euros   2014   2013   Δ
Products   2,612   2,306   +13%
Services 309 286 +8%
First-quarter sales   2,921   2,592   +13%
Products 4,788 3,923 +22%
Services 410 387 +6%
Second-quarter sales   5,198   4,310   +21%
Products 3,924 3,245 +21%
Services 505 389 +30%
Third-quarter sales   4,429   3,634   +22%
Products 6,808 6,120 +11%
Services 406 304 +33%
Fourth-quarter sales   7,214   6,425   +12%
Products 18,132 15,595 +16%
Services 1,630 1,366 +19%
Total sales   19,761   16,961   +17%
Other revenue (*)   1,819   -   -
Total revenue   21,580   16,961   +27%

Audited data

Note (*): these activities are not part of the Group’s core business and the associated revenue will not occur regularly.

SuperSonic Imagine’s annual revenue for FY 2014 totaled €21.6 million, up +27% compared with December 31, 2013. These figures include Other Revenue, essentially derived from technology access fees and collaborative product development.

Over the year, sales increased from €17.0 million to €19.8 million, representing an annual growth of +17%, mainly driven by Asia, followed by the Americas and France. Product sales and Services sales totaled €18.1 million and €1.6 million respectively, or 92% and 8% of annual sales.

Over the 4th quarter of 2014, SuperSonic Imagine recorded €7.2 million in sales, a +12% increase compared with the same quarter of 2013. Asia generated buoyant growth over the quarter, where the organization that has been put in place fully met expectations, closely followed by the EMEA zone. In the Americas, despite solid growth in direct sales, the Company recorded a weaker performance overall as a result of a slowdown in indirect sales in the United States. Over the quarter, Services sales totaled €406 thousand and were thus up a buoyant +33% on the €304 thousand recorded over the same quarter of the previous year.

Jacques Souquet, SuperSonic Imagine’s Founder and CEO, concludes: “We are pleased with the strong sales performance delivered by our direct sales force. This validates our expansion strategy across all of our markets, both in terms of Products and in terms of the growth of our Services activity, which is a pivotal part of our development policy. We are confident that the medical value of our advanced ultrasound platform will become increasingly recognized and its global adoption will continue in 2015.”

Next press release: 2014 full-year results, on March 16, 2015

About SuperSonic Imagine
Founded in 2005 and based in Aix-en-Provence (France), SuperSonic Imagine is a company specializing in medical imaging.
The company designs, develops and markets a revolutionary ultrasound system, Aixplorer®, with an UltraFast™ platform that can acquire images 200 times faster than conventional ultrasound systems. Aixplorer® is the only system that can image two types of waves: ultrasound waves ensure excellent image quality and shear waves, which allow physicians to visualize and analyze the stiffness of tissue in a real-time, reliable, reproducible and non-invasive manner. This innovation, ShearWave™ Elastography, significantly improves the detection and characterization of numerous pathologies in several applications including breast, thyroid, liver and prostate. SuperSonic Imagine has been granted regulatory clearances for the commercialization of Aixplorer® in the main global markets. Over the past years, SuperSonic Imagine enjoyed the backing of several prestigious investors, among which Auriga Partners, Edmond de Rothschild Investment Partners, Bpifrance, Omnes Capital and NBGI.

For more information about SuperSonic Imagine, please go to www.supersonicimagine.com